Loading
Sacituzumab tirumotecan / Cisplatin / Pembrolizumab · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 trial registration for sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab monotherapy in resectable NSCLC patients who did not achieve pathological complete response. No efficacy or safety results are posted; the study is currently recruiting and follow-up continues up to approximately 93 months for disease-free survival assessment.
Phase 3, Interventional, Non Randomized, Parallel, Single masking, Treatment purpose. Non Small Cell Lung Cancer; age from 18 Years. Intervention: Pembrolizumab + Sacituzumab tirumotecan. Compared with: Pembrolizumab — Active Comparator. n = 780. 268 sites across 31 countries.
This is a Phase 3 trial registration for sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab monotherapy in resectable NSCLC patients who did not achieve pathological complete response. No efficacy or safety results are posted; the study is currently recruiting and follow-up continues up to approximately 93 months for disease-free survival assessment.
No efficacy or safety results are posted in this registry record; outcomes cannot be assessed Primary outcome is disease-free survival; overall survival and long-term safety data are not yet available
If positive, this trial could establish a new adjuvant regimen for NSCLC patients with incomplete pathological response; however, no clinical guidance can be drawn from a registry record without posted results.
This is a Phase 3 trial registration with no posted results; the study is actively recruiting and outcome data are not yet available for evaluation.
As stated by the source record.
Quoted from the source exactly as published.
If positive, this trial could establish a new adjuvant regimen for NSCLC patients with incomplete pathological response; however, no clinical guidance can be drawn from a registry record without posted results.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06312137). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 780 participants (ESTIMATED). Conditions: Non Small Cell Lung Cancer. Interventions: BIOLOGICAL: Sacituzumab tirumotecan; BIOLOGICAL: Pembrolizumab; DRUG: Cisplatin; DRUG: Pemetrexed; DRUG: Gemcitabine; DRUG: Carboplatin; DRUG: Paclitaxel; DRUG: Rescue medication. Primary outcome measures: Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR) , Up to ~ 93 months. Brief summary: This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.